Cognition Therapeutics Inc
NASDAQ:CGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cognition Therapeutics Inc
Non-Reccuring Items
Cognition Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Non-Reccuring Items
-$2.4B
|
CAGR 3-Years
38%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Non-Reccuring Items
-$6.9B
|
CAGR 3-Years
-59%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-24%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Non-Reccuring Items
-$10.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-12%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Non-Reccuring Items
-$5.6B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Non-Reccuring Items
-$3.4B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-12%
|
|
Cognition Therapeutics Inc
Glance View
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
